The math is pretty simple: all the drivers being allocated proportionally, it's a lot easier to grow a small revenue base faster than a large one. And since investors reward growth more richly than cash flow, the biotechs' ability to grow should trump Big Pharma's stability.
But because the resources haven't been remotely equivalent, the biotech industry has always positioned itself, somewhat uncomfortably, to serve the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?